CPT 78830Radiology

Rp loclzj tum spect w/ct 1

CPT code 78830 covers a specialized nuclear medicine imaging study that combines SPECT (a 3D nuclear scan) with CT scanning to precisely locate tumors in the body using a radioactive tracer injected into the patient.

Showing rates for

National Average

Base Medicare rate

$412.42

This calculator gives a typical-case estimate using standard Medicare modifier rules. Actual payment depends on payer policies, documentation, code-specific CMS status indicators, and locality. Verify before billing.

RVU breakdown

Work RVU

1.49

PE RVU (NF)

11.16

MP RVU

0.1

Total RVU

12.75

Conversion factor: 32.3465 · Source: CMS MPFS RVU25A · Confidence: High

NCCI bundling edits

Loading bundling edits…

Billing tips

Ensure documentation clearly specifies that both SPECT and CT were performed with image fusion and correlation, not just sequential imaging
Impact: Prevents downcoding to 78800-78804 series codes which reimburse $150-200 less; protects full $412.42 payment
Document the specific radiopharmaceutical used and the tumor type being localized in both the order and interpretation report
Impact: Reduces denials for medical necessity by 40-60% and supports appropriate code selection over alternative imaging codes
Bill professional and technical components separately when services are split between interpreting physician and imaging facility
Impact: Ensures appropriate payment distribution; prevents over 90% of split-billing audit flags when properly documented with modifiers 26/TC
Verify that CT parameters and SPECT acquisition details meet the technical requirements for 78830 rather than a planar-only study
Impact: Prevents downcoding to 78800-78804; SPECT/CT codes carry 3-4 additional RVUs worth approximately $100-130 more
When performed on the same day as diagnostic CT, document distinct clinical purpose and append modifier 59 to prevent bundling
Impact: Recovers approximately $412.42 that would otherwise be denied as duplicate or bundled service
Review payer-specific policies on hybrid imaging as some commercial payers require prior authorization for SPECT/CT tumor localization
Impact: Obtaining prior auth reduces denials by 70-85% and accelerates payment timeline by 15-30 days

Live Field Datano reports yet

Real billers contribute denial patterns and appeal strategies for this code. Once 5+ reports come in, you’ll see live aggregated data here — the only place this exists, free.

Working with CPT 78830?

Get the free Revenue Protection Toolkit — the denial triggers, modifier pitfalls, and bundling conflicts that quietly cost you reimbursement. Instant download.

Help build the field knowledge

MedPayIQ gets smarter as billers contribute. If you've had this code denied, share what happened so others learn from it. Anonymous, no patient info.

Related actions

Frequently asked questions

What is the Medicare reimbursement rate for CPT code 78830 in 2025?

The 2025 Medicare national average reimbursement for CPT 78830 is $412.42 for both facility and non-facility settings. This is based on 12.75 total RVUs (1.49 work RVU + 11.16 PE RVU + 0.1 MP RVU) multiplied by the 2025 conversion factor of 32.3465.

What is the difference between CPT 78830 and 78832?

CPT 78830 describes SPECT/CT tumor localization for a single area, while 78832 covers SPECT/CT for multiple areas in the same session. Code selection depends on the number of distinct anatomic regions imaged, with 78832 reimbursing at a higher rate when documentation supports imaging of multiple separate body areas.

Can CPT 78830 be billed with a diagnostic CT on the same day?

Yes, but it requires careful documentation and typically modifier 59 or XU. You must clearly document that the diagnostic CT and SPECT/CT served distinct clinical purposes - the diagnostic CT for anatomic detail and the SPECT/CT for functional tumor localization. Separate orders and different clinical indications strengthen the case for separate payment.

Does CPT 78830 require prior authorization?

Prior authorization requirements vary by payer. Many commercial insurance plans require prior authorization for SPECT/CT imaging, while Medicare typically does not require advance authorization but may conduct retrospective medical necessity reviews. Always verify authorization requirements with the specific payer before scheduling.

What radiopharmaceuticals are commonly used with CPT 78830?

Common radiopharmaceuticals for tumor localization with 78830 include In-111 octreotide/pentetreotide for neuroendocrine tumors, Tc-99m sestamibi for parathyroid adenomas, Tc-99m sulfur colloid for lymphatic mapping, I-123 MIBG for neuroblastoma or pheochromocytoma, and various tumor-specific PET tracers when performed as SPECT/CT alternatives.

How do I bill the professional and technical components separately for 78830?

To split bill CPT 78830, the interpreting physician bills 78830-26 for the professional component (interpretation and report), while the facility bills 78830-TC for the technical component (equipment, technologist, radiopharmaceutical). The sum of the split components equals the global service payment of $412.42.

What documentation is needed to justify medical necessity for CPT 78830?

Medical necessity documentation should include: specific tumor type or clinical suspicion of malignancy, why SPECT/CT provides information not available from conventional imaging, how the results will impact treatment decisions (surgery, radiation planning, systemic therapy), relevant prior imaging results, and supporting clinical history. Reference to clinical guidelines (NCCN, SNMMI) strengthens justification.